bone morphogenetic protein (BMP) portfolio of development programs and associated intellectual property.
The portfolio includes a next-generation BMP in development designed to
offer additional options to currently marketed BMP products and the rights to re-combinant bone morphogenetic protein-2
(rhBMP-2, a controversial synthetic bone
growth factor often used as a bone graft
substitute) in indications and fields previously reserved for Pfizer, according to
a recent announcement from Bioventus,
which also acquired an exclusive option to
a BMP program for soft tissue indications.
Pfizer has agreed to transfer to Bio-
ventus all existing development work for
the BMP assets and to undertake certain
early development activities relating to
the next-generation BMP. Pfizer also will
manufacture rhBMP-2 and supply it to
Bioventus. Though financial details were
not disclosed, under the terms of the
license agreement, Pfizer received an
upfront payment and will be eligible to
receive milestone payments and royalties
on any sales.